NRM-823 is a novel T-cell engager designed to target a specific tumor antigen prevalent in advanced prostate cancer. Preclinical studies have demonstrated its ability to effectively redirect T cells to recognize and destroy prostate cancer cells, leading to significant tumor reduction.
This innovative approach offers a promising therapeutic avenue for patients with treatment-resistant prostate cancer, potentially enhancing outcomes by leveraging the body's immune response.
Phase 1 clinical trial should start in the second half of 2025.
